Material Event - Form 8-K

Item 8.01 Other Events.

As previously disclosed, on May 26, 2023, Nektar Therapeutics (the "Company") received a notice from the Nasdaq Listing Qualifications Department (the "Staff") stating that the Company was not in compliance with the minimum bid price requirement of $1.00 per share (the "Minimum Bid Price Requirement") for continued listing on the Nasdaq Global Market because the Company's common stock did not maintain a minimum closing bid price of $1.00 per share or greater for 30 consecutive business days. The Company was given an initial 180 calendar day period, or until November 22, 2023, to regain compliance with the Minimum Bid Price Requirement. On November 24, 2023, the Company received another notice from the Staff stating that the Company was eligible for an additional 180 calendar day period, or until May 20, 2024, to regain compliance with the Minimum Bid Price Requirement. The Company's common stock was transferred from the Nasdaq Global Select Market to the Nasdaq Capital Market at the opening of business on November 28, 2023.

On April 17, 2024, the Company received a letter from the Staff notifying the Company that it has regained compliance with the Minimum Bid Price Requirement for continued listing on the Nasdaq Capital Market. To regain compliance with the Minimum Bid Price Requirement, the Company's common stock was required to maintain a closing bid price of $1.00 per share or greater for at least 10 consecutive business days. This requirement was met on April 16, 2024.